Navin Fluorine International Limited has announced the approval of a INR 236.5 crore capex for setting up additional HFC capacity and a INR 75 crore capex for debottlenecking its MPP capacity. The company reported strong Q2 FY26 results with revenue of INR 758 crores, up 46% year-over-year, and EBITDA of INR 246 crores, up 129% year-over-year. An interim dividend of INR 6.5 per share was also declared.
Strategic Capex Approvals
The Board of Directors has approved two strategic capital expenditure projects:
- A INR 236.5 crore investment to establish additional HFC capacity for producing up to 15,000 metric tonnes per annum of R32, addressing global demand for transitioning to low GWP commitments. This asset is projected to generate peak annual revenue of INR 600 crores to INR 825 crores upon completion.
- A INR 75 crore investment for debottlenecking the Multi-Purpose Plant (MPP) capacity at Dahej, expected to contribute INR 140 crores to INR 160 crores per annum upon completion.
Both capexes will be funded through internal accruals.
Financial Performance Highlights
The company reported strong financial results for Q2 FY26:
- Revenue: INR 758 crores, a 46% increase year-over-year.
- EBITDA: INR 246 crores, a 129% increase year-over-year, with a margin of 32.5%.
- Profit after tax: INR 148 crores, more than double compared to INR 59 crores in Q2 FY25.
For the first half of FY26:
- Revenue: INR 1,484 crores, a 42% increase over the previous year.
- EBITDA: INR 453 crores, compared to INR 208 crores in the previous year, with margins at 30.5%.
- Profit after tax: INR 266 crores, a 141% growth year-over-year.
Business Segment Performance
All three business divisions (HPP, Specialty, and CDMO) reported good growth in Q2 FY26.
- HPP business revenue crossed INR 400 crores, a 38% increase year-on-year.
- Specialty business revenue grew by 39% year-on-year to INR 220 crores.
- CDMO business revenue grew by 98% year-on-year to INR 134 crores.
Additional Updates
- The AHF project is advancing steadily, with commissioning expected by Q3 FY26.
- The company received a firm order for calendar year 2026 from a global innovator to manufacture a key intermediate for their novel AI.
- Supplies commencing from January 2026 from the cGMP4 plant.
An interim dividend of INR 6.5 per share has been declared.
Source: BSE